by Stephanie Reid, MD FRCPC
November 17, 2026
Steatohepatitis is a liver disease in which fat buildup in liver cells is accompanied by inflammation and injury. It is not cancer. It is more serious than fat alone because the ongoing injury can lead to scarring of the liver over time. With treatment of the cause, steatohepatitis can improve, and early scarring can partly heal.
This article explains what steatohepatitis means, how pathologists recognize it on a liver biopsy, and what the activity score and fibrosis stage in your report describe. It also explains the newer names, such as MASH, and the treatments now available.
The word steatohepatitis joins two parts. “Steato” means fat, and “hepatitis” means inflammation of the liver. In steatosis, liver cells called hepatocytes store too much fat but are otherwise healthy. In steatohepatitis, the fat is accompanied by signs that the cells are being damaged and that the body is reacting to that damage.
When liver cells are injured repeatedly, the liver tries to repair itself by laying down scar tissue, called fibrosis. If the injury continues for many years, the scarring can spread across the liver and lead to cirrhosis. This is why doctors pay close attention to steatohepatitis even when a person feels well.
Steatohepatitis is named by its cause. The names changed in 2023, when international liver societies agreed on new terms, so your report may use either the older or the newer name.
Our article on steatosis lists the full set of new names and the risk factors used to define them.
Most people with steatohepatitis have no symptoms until the liver is badly scarred. The condition is often suspected because of raised liver enzymes on a liver blood test panel or a fatty liver seen on an ultrasound. Some people feel tired or have discomfort in the upper right side of the abdomen.
When cirrhosis develops, symptoms can include yellowing of the skin and eyes, called jaundice, swelling of the legs or abdomen, and easy bruising. Severe alcohol-related steatohepatitis can also cause a sudden illness called alcohol-associated hepatitis, with jaundice that comes on quickly and can lead to liver failure.
Steatohepatitis can only be confirmed by examining liver tissue under a microscope. Blood tests and scans that measure liver stiffness can estimate how much scarring is present, and many people are now managed with these tests alone. A liver biopsy is done when the diagnosis is uncertain, when another liver disease may also be present, or when the amount of scarring will change treatment.
During a needle biopsy, a thin core of liver tissue is removed and sent to a pathologist. The pathologist determines whether steatohepatitis is present by assessing the overall pattern of injury, not by adding up a score. A trichrome stain, which colors scar tissue blue, is used to judge the amount of fibrosis. An iron stain is often added to detect excess iron.
Steatohepatitis is diagnosed when the pathologist sees a characteristic group of changes. In adults, these changes usually begin around the small veins in the center of each liver unit, an area pathologists call zone 3. Your report may describe some or all of the following features:
In children, steatohepatitis often looks different. The scarring tends to start around the portal tracts rather than in zone 3. Portal tracts are the small channels that carry blood vessels and bile ducts through the liver.
Alcohol-related steatohepatitis and metabolic steatohepatitis look very similar under the microscope. A pathologist usually cannot be sure of the cause from the biopsy alone. Your doctor makes the final decision by combining the biopsy with your medical history, alcohol use, and blood tests.
Some features are more common with alcohol, and the report may mention them:
Many pathologists give a NAFLD activity score, also called NAS or the activity grade, when steatohepatitis is diagnosed. The NASH Clinical Research Network developed the score in 2005. The name may change in the future to match the new terms, but most reports still use NAS. It adds three separate scores:
The total ranges from 0 to 8. In the original study, scores of 5 or more were seen mostly in biopsies with steatohepatitis, and scores of 0 to 2 were seen mostly in biopsies without it. Scores of 3 or 4 fell in between. The NAS describes how active the disease is today. It does not measure scarring, and it is not used alone to make the diagnosis.
Some pathologists, especially in Europe, use the SAF score instead. SAF stands for steatosis, activity, and fibrosis, and it reports the same features slightly differently.
The fibrosis stage describes how much scarring is present and where it is found. It is the most important finding in a steatohepatitis biopsy because it predicts long-term liver health better than any other feature. Most reports use the NASH Clinical Research Network stages:
Doctors often group these stages. Stage 2 is called significant or moderate fibrosis, stage 3 is called advanced fibrosis, and stage 4 is cirrhosis. Your report may write the stage as F0 to F4.
Steatohepatitis is a slowly changing disease, and it can move in either direction. A large review of repeat biopsies found that scarring advanced by about one stage every 7 years, on average, in people with steatohepatitis. In people with steatosis alone, the same change took about 14 years. Another analysis found that steatohepatitis went away in about 29% of people over a median of 3.5 years.
The fibrosis stage is the strongest predictor of what happens next. People with no scarring or stage 1 fibrosis have a low risk of serious liver problems over the following decades. The risk rises with stage 3 and is highest with cirrhosis, which can lead to liver failure and hepatocellular carcinoma, a type of liver cancer. People with metabolic steatohepatitis also have a higher risk of heart disease, which is often the bigger threat to their health.
After pathology confirms steatohepatitis, treatment focuses on addressing the cause and stopping scarring from advancing. The fibrosis stage in your report guides how closely your liver is watched and whether medication is considered.
Two medications are approved for adults with metabolic steatohepatitis and stage 2 or 3 fibrosis who do not have cirrhosis. Both are used together with diet and exercise.
These approvals are based on improvements seen on liver biopsies after about one to one and a half years of treatment. Studies of their effect on long-term outcomes, such as cirrhosis and survival, are still under way. Medications are not approved for steatohepatitis without significant scarring, or for steatosis alone.
Most people are followed with blood tests and liver stiffness scans rather than repeat biopsies. A hepatologist, a doctor who specializes in the liver, is often involved when the fibrosis stage is 2 or higher. People with cirrhosis are offered regular ultrasound scans to look for early liver cancer.
🔍 Search MyPathologyReport
Type what you see on your report — for example a diagnosis or test name